Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Diabetic Macular Edema
NCT03453281Phase 4Completed
- Sponsor
- Universitas Indonesia
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Universitas Indonesia. Primary endpoint: Central macular thickness at 1 month. Started Oct 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03453281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453281.